CN112089800A - 治疗弥漫性间质性肺纤维化肺炎中药组合物及其制备方法 - Google Patents
治疗弥漫性间质性肺纤维化肺炎中药组合物及其制备方法 Download PDFInfo
- Publication number
- CN112089800A CN112089800A CN202011158979.7A CN202011158979A CN112089800A CN 112089800 A CN112089800 A CN 112089800A CN 202011158979 A CN202011158979 A CN 202011158979A CN 112089800 A CN112089800 A CN 112089800A
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- pulmonary fibrosis
- chinese medicine
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 50
- 206010035664 Pneumonia Diseases 0.000 title claims abstract description 37
- 239000000203 mixture Substances 0.000 title claims abstract description 33
- 208000029523 Interstitial Lung disease Diseases 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 16
- 239000002994 raw material Substances 0.000 claims abstract description 15
- 240000005373 Panax quinquefolius Species 0.000 claims abstract description 9
- 241001313857 Bletilla striata Species 0.000 claims abstract description 8
- 241000255789 Bombyx mori Species 0.000 claims abstract description 8
- 241000931705 Cicada Species 0.000 claims abstract description 8
- 244000268590 Euryale ferox Species 0.000 claims abstract description 8
- 235000011201 Ginkgo Nutrition 0.000 claims abstract description 8
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 8
- 244000194101 Ginkgo biloba Species 0.000 claims abstract description 8
- 240000000691 Houttuynia cordata Species 0.000 claims abstract description 8
- 235000013719 Houttuynia cordata Nutrition 0.000 claims abstract description 8
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 8
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims abstract description 8
- 240000006079 Schisandra chinensis Species 0.000 claims abstract description 8
- 235000008422 Schisandra chinensis Nutrition 0.000 claims abstract description 8
- 235000008434 ginseng Nutrition 0.000 claims abstract description 8
- 244000237330 gutta percha tree Species 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims abstract description 7
- 210000000582 semen Anatomy 0.000 claims abstract description 7
- 240000000031 Achyranthes bidentata Species 0.000 claims abstract description 6
- 241000382455 Angelica sinensis Species 0.000 claims abstract description 6
- 241000045403 Astragalus propinquus Species 0.000 claims abstract description 6
- 241000270666 Testudines Species 0.000 claims abstract description 6
- 241000270708 Testudinidae Species 0.000 claims abstract description 6
- 235000006533 astragalus Nutrition 0.000 claims abstract description 6
- 240000000377 Tussilago farfara Species 0.000 claims abstract description 5
- 235000004869 Tussilago farfara Nutrition 0.000 claims abstract description 5
- 244000248539 Asparagus cochinchinensis Species 0.000 claims abstract description 3
- 235000009292 Asparagus cochinchinensis Nutrition 0.000 claims abstract description 3
- 235000006487 Euryale ferox Nutrition 0.000 claims abstract description 3
- 241000361919 Metaphire sieboldi Species 0.000 claims abstract description 3
- 241001478428 Syngnathus Species 0.000 claims abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 238000002791 soaking Methods 0.000 claims description 19
- 244000131316 Panax pseudoginseng Species 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 12
- 241000005787 Cistanche Species 0.000 claims description 7
- 241001523681 Dendrobium Species 0.000 claims description 7
- 101000831205 Danio rerio Dynein axonemal assembly factor 11 Proteins 0.000 claims description 5
- 102100024282 Dynein axonemal assembly factor 11 Human genes 0.000 claims description 5
- 241001559542 Hippocampus hippocampus Species 0.000 claims description 5
- 101000831210 Homo sapiens Dynein axonemal assembly factor 11 Proteins 0.000 claims description 5
- 241000243684 Lumbricus Species 0.000 claims description 5
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims description 5
- 244000003416 Asparagus officinalis Species 0.000 claims description 4
- 235000005340 Asparagus officinalis Nutrition 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 241000628997 Flos Species 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 244000061520 Angelica archangelica Species 0.000 claims description 2
- 244000077995 Coix lacryma jobi Species 0.000 claims description 2
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 2
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 2
- 240000002948 Ophiopogon intermedius Species 0.000 claims description 2
- 241000218206 Ranunculus Species 0.000 claims description 2
- 229940107666 astragalus root Drugs 0.000 claims description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 2
- 235000011477 liquorice Nutrition 0.000 claims description 2
- 239000008517 radix Trichosanthis Substances 0.000 claims description 2
- 230000001575 pathological effect Effects 0.000 abstract description 6
- 241000180649 Panax notoginseng Species 0.000 abstract description 3
- 235000003143 Panax notoginseng Nutrition 0.000 abstract description 3
- 210000001320 hippocampus Anatomy 0.000 abstract description 3
- 230000008033 biological extinction Effects 0.000 abstract description 2
- 230000004069 differentiation Effects 0.000 abstract description 2
- 238000002309 gasification Methods 0.000 abstract description 2
- 238000001727 in vivo Methods 0.000 abstract description 2
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 230000009466 transformation Effects 0.000 abstract description 2
- 241000336315 Cistanche salsa Species 0.000 abstract 1
- 241000218989 Trichosanthes Species 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 description 69
- 238000011282 treatment Methods 0.000 description 21
- 239000008280 blood Substances 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 16
- 210000002216 heart Anatomy 0.000 description 15
- 210000003734 kidney Anatomy 0.000 description 14
- 208000000059 Dyspnea Diseases 0.000 description 11
- 206010013975 Dyspnoeas Diseases 0.000 description 11
- 238000003745 diagnosis Methods 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 10
- 210000000038 chest Anatomy 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 210000001370 mediastinum Anatomy 0.000 description 10
- 229910052760 oxygen Inorganic materials 0.000 description 10
- 239000001301 oxygen Substances 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 241000711573 Coronaviridae Species 0.000 description 8
- 238000010586 diagram Methods 0.000 description 8
- 238000003384 imaging method Methods 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 208000005069 pulmonary fibrosis Diseases 0.000 description 7
- 230000029058 respiratory gaseous exchange Effects 0.000 description 7
- 206010008479 Chest Pain Diseases 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 230000002146 bilateral effect Effects 0.000 description 6
- 210000004351 coronary vessel Anatomy 0.000 description 6
- 208000028659 discharge Diseases 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 210000004224 pleura Anatomy 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 206010011224 Cough Diseases 0.000 description 5
- 206010013954 Dysphoria Diseases 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 210000001165 lymph node Anatomy 0.000 description 5
- 238000002640 oxygen therapy Methods 0.000 description 5
- 206010014561 Emphysema Diseases 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 4
- 206010021143 Hypoxia Diseases 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 206010033557 Palpitations Diseases 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 210000000621 bronchi Anatomy 0.000 description 4
- 230000002308 calcification Effects 0.000 description 4
- 208000029078 coronary artery disease Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000004761 fibrosis Effects 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 208000013220 shortness of breath Diseases 0.000 description 4
- 210000003437 trachea Anatomy 0.000 description 4
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 3
- 206010011703 Cyanosis Diseases 0.000 description 3
- 206010022998 Irritability Diseases 0.000 description 3
- 206010035737 Pneumonia viral Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000002376 aorta thoracic Anatomy 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000007954 hypoxia Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 210000003516 pericardium Anatomy 0.000 description 3
- 210000003281 pleural cavity Anatomy 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000007958 sleep Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 208000009421 viral pneumonia Diseases 0.000 description 3
- 208000003322 Coinfection Diseases 0.000 description 2
- 208000006083 Hypokinesia Diseases 0.000 description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 2
- 208000032376 Lung infection Diseases 0.000 description 2
- 208000002720 Malnutrition Diseases 0.000 description 2
- 206010035600 Pleural fibrosis Diseases 0.000 description 2
- 208000037656 Respiratory Sounds Diseases 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 201000001352 cholecystitis Diseases 0.000 description 2
- 208000026758 coronary atherosclerosis Diseases 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 230000001861 immunosuppressant effect Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000011866 long-term treatment Methods 0.000 description 2
- 230000001071 malnutrition Effects 0.000 description 2
- 235000000824 malnutrition Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 208000015380 nutritional deficiency disease Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000002636 symptomatic treatment Methods 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 206010001889 Alveolitis Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 206010052770 Coma states Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000034657 Convalescence Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 241000935926 Diplodia Species 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 241000521257 Hydrops Species 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010025102 Lung infiltration Diseases 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 206010040007 Sense of oppression Diseases 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 210000004289 cerebral ventricle Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000011863 diuretic therapy Methods 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 230000037080 exercise endurance Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
- 230000008921 facial expression Effects 0.000 description 1
- 229960002848 formoterol Drugs 0.000 description 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000005338 frosted glass Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 210000003361 heart septum Anatomy 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
- 208000018875 hypoxemia Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 229940125386 long-acting bronchodilator Drugs 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 201000003102 mental depression Diseases 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 229940126677 modern western medicines Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 235000017924 poor diet Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000009863 secondary prevention Effects 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229960000257 tiotropium bromide Drugs 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/58—Reptiles
- A61K35/583—Snakes; Lizards, e.g. chameleons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/58—Reptiles
- A61K35/586—Turtles; Tortoises, e.g. terrapins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/36—Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/428—Trichosanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/64—Orobanchaceae (Broom-rape family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/78—Saururaceae (Lizard's-tail family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8965—Asparagus, e.g. garden asparagus or asparagus fern
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8984—Dendrobium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Insects & Arthropods (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Marine Sciences & Fisheries (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Animal Husbandry (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了治疗弥漫性间质性肺纤维化肺炎中药组合物及其制备方法。属于中药技术领域。包括以下原料:人参须、麦冬、蝉蜕、白芨、茯神、丹皮、当归、蛤蚧、海龙、海马、蚕蛹、石斛、壁虎、鹿角霜、白果、黄芪、地龙、芡实、薏苡仁、西洋参、天冬、肉苁蓉、黄精、五味子、牛膝、款冬花、三七参、鱼腥草、杜仲、太子参、天花粉、猫爪草、龟板、鳖甲和甘草。本发明促进病理细胞自身体内的转变分化和消亡,经多方位的气化演变,将病理细胞分别逆转和修复为正常生理细胞。
Description
技术领域
本发明涉及中药技术领域,更具体的说是涉及治疗弥漫性间质性肺纤维化肺炎中药组合物及其制备方法。
背景技术
目前,特发性肺纤维化(包括多种具体病症,如弥漫性淋巴组织间质性纤维化肺炎等),有的观点主张在间质组织增生期,适用免疫抑制剂,能防止纤维化和肺容量的损害,但若已形成不可逆转的纤维组织,免疫抑制剂无效。其他疗法均为对症,例如,低氧症可给予流量氧吸入,在吸氧期间,紫绀改善,运动耐力进步,但无法脱离氧疗。
故而,弥漫性淋巴组织间质性纤维化肺炎目前尚无特效的疗法,大剂量强的松(60mg/d),有的病例症状进步,X线病灶吸收;然而有的病例,用药后肺部浸润,不久又恶化。由于缺乏对照,故皮质激素的效果很难作正确的评价。也有使用环磷酰胺和长春新碱等抗肿瘤药物治疗,效果不确实。
而对于特发性肺纤维化关联的外源性变应性肺泡炎:一旦得病,需脱离接触隔离,卧床休息,呼吸困难和紫绀显著者应给与氧疗,抗生素可适当给予,以防继发感染,大剂量强的松(60mg/d)干预,口服四周后,逐渐减量,以至停用。患者应避免再度接触已知的致病抗原,慢性型肺纤维组织增生,激素仅能减低肺部炎症的程度。
此外,新冠肺炎康复患者,部分也出现肺纤维化趋势,目前难于确定是否为后遗症,但会造成部分患者烦躁不安、缺氧、运动不畅等典型或非典型肺纤维化系列症状。
不难看出,现代西药在治疗弥漫性、间质性、肺纤维化肺炎(条索灶)时,无法根治。
因此,能否提供一种治疗弥漫性间质性肺纤维化肺炎中药组合物及其制备方法,达到临床治愈,显著改善患者病情是本领域技术人员亟需解决的问题。
发明内容
有鉴于此,本发明提供了治疗弥漫性间质性肺纤维化肺炎中药组合物及其制备方法。
为了实现上述目的,本发明采用如下技术方案:
一种治疗弥漫性间质性肺纤维化肺炎中药组合物,包括以下重量份的原料:人参须20~30份、麦冬15~25份、蝉蜕20~30份、白芨15~25份、茯神15~25份、丹皮15~25份、当归15~25份、蛤蚧10~15份、海龙10~20份、海马10~20份、蚕蛹20~30份、石斛15~25份、壁虎10~20份、鹿角霜15~25份、白果15~25份、黄芪15~25份、地龙15~25份、芡实15~25份、薏苡仁20~30份、西洋参15~25份、天冬15~25份、肉苁蓉20~30份、黄精15~25份、五味子15~25份、牛膝15~25份、款冬花15~25份、三七参15~25份、鱼腥草15~25份、杜仲15~25份、太子参15~25份、天花粉15~25份、猫爪草15~30份、龟板20~40份、鳖甲20~40份和甘草10~20份。
优选的:包括以下重量份的原料:人参须25份、麦冬20份、蝉蜕25份、白芨20份、茯神20份、丹皮20份、当归20份、蛤蚧12份、海龙15份、海马15份、蚕蛹25份、石斛20份、壁虎15份、鹿角霜20份、白果20份、黄芪20份、地龙20份、芡实20份、薏苡仁25份、西洋参20份、天冬20份、肉苁蓉25份、黄精20份、五味子20份、牛膝20份、款冬花20份、三七参20份、鱼腥草20份、杜仲20份、太子参20份、天花粉20份、猫爪草25份、龟板30份、鳖甲30份和甘草15份。
有益效果在于:上述药材的组合促进病理细胞自身体内的转变分化和消亡,经多方位的气化演变,将病理细胞分别逆转和修复为正常生理细胞。
本发明还提供了一种治疗弥漫性间质性肺纤维化肺炎中药组合物的制备方法,包括以下步骤:
(1)预煎煮:将龟板和鳖甲混合后,加水,水浴煎煮,得混合药液A,备用;
(2)将上述其余原料混合置于水中浸泡后取出备用;
(3)煎煮:将混合药液A和步骤(2)浸泡后的原料混合得料B,置于水中浸泡,再加热煎煮,留药液,重复浸泡和煎煮,合并药液。有益效果在于:
有益效果在于:步骤(2)、(3)的浸泡有利于提高药材在煎煮过程中,充分释放活性物质。
优选的:步骤(1)煎煮的温度为100~102℃,煎煮时间为18~22min。
优选的:步骤(1)所述龟板加鳖甲总质量与水的体积比为(4~8)g:(25~35)ml。
优选的:步骤(2)水的温度为1~10℃,浸泡时间为85~95min。
优选的:步骤(3)重复次数为一次;浸泡温度85~100℃,浸泡时间55~65min。
优选的:步骤(3)煎煮的温度为100℃,煎煮时间为45~55min。
优选的:步骤(3)所述料B和水的质量体积比为1g:(8~12)ml。
本发明还提供了上述中药组合物或上述方法制备的中药组合物在制备治疗新冠性肺炎药物中的应用。
经由上述的技术方案可知,与现有技术相比,本发明公开提供了治疗弥漫性间质性肺纤维化肺炎中药组合物及其制备方法,取得的技术效果为,服用本发明配方患者,可以明显改善肺纤维化症状(包括影像学鉴定),明显恢复生活质量,达到脱氧,正常工作生活,达到临床治愈的效果。
其中,在治疗新型冠状病毒肺炎后遗症这一病种有独特的优势,辩证论治的基础上;以固本清源,标本兼治,润肺补肾,散结化瘀、益气补血,在分化病毒的同时,将病理细胞逆转和修复为正常生理细胞;
在针对气阴两虚、肺失需养、蕴毒臃盛、气滞血瘀,即肺上叶间质性炎症,肺间质性改变病症,以润肺生津、健脾补肾、和胃养血、清热解毒、理气散结化瘀进行施治,达到“肺为气之主,肾为气之根。肺主出气,肾主纳气,阴阳相交,呼吸乃和”。
附图说明
为了更清楚地说明本发明实施例或现有技术中的技术方案,下面将对实施例或现有技术描述中所需要使用的附图作简单地介绍,显而易见地,下面描述中的附图仅仅是本发明的实施例,对于本领域普通技术人员来讲,在不付出创造性劳动的前提下,还可以根据提供的附图获得其他的附图。
图1附图为本发明新冠后遗症患者提供的首次检查报告示意图。
图2附图为本发明新冠后遗症患者提供的第二次检查报告示意图。
图3附图为本发明新冠后遗症患者提供的第三次检查报告示意图。
图4附图为本发明新冠后遗症患者提供的第四次检查报告示意图。
图5附图为本发明新冠后遗症患者提供的第五次检查报告示意图。
图6附图为本发明新冠后遗症患者提供的第六次检查报告示意图。
图7附图为本发明新冠后遗症患者提供的第七次检查报告示意图。
图8附图为本发明右肺上叶间质性炎症,双肺间质性改变患者检查报告示意图。
图9附图为本发明右肺上叶间质性炎症,双肺间质性改变患者近期出院医嘱示意图。
具体实施方式
下面将结合本发明实施例中的附图,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
本发明实施例公开了治疗弥漫性间质性肺纤维化肺炎中药组合物及其制备方法。
实施例中所涉及药材原料均为市售渠道获得,对其品牌不做要求,未提及的方法为常规实验方法。其中,为保护患者及医师隐私,报告敏感信息如姓名、门诊号、床号、报告编号等均已做处理。
实施例1
一种治疗弥漫性间质性肺纤维化肺炎中药组合物,包括以下重量的原料:人参须20g、麦冬15g、蝉蜕20g、白芨15g、茯神15g、丹皮15g、当归15g、蛤蚧10g、海龙10g、海马10g、蚕蛹20g、石斛15g、壁虎10g、鹿角霜15g、白果15g、黄芪15g、地龙15g、芡实15g、薏苡仁20g、西洋参15g、天冬15g、肉苁蓉20g、黄精15g、五味子15g、牛膝15g、款冬花15g、三七参15g、鱼腥草15g、杜仲15g、太子参15g、天花粉15g、猫爪草15g、龟板20g、鳖甲20g和甘草10g。
实施例2
一种治疗弥漫性间质性肺纤维化肺炎中药组合物,包括以下重量的原料:人参须25g、麦冬20g、蝉蜕25g、白芨20g、茯神20g、丹皮20g、当归20g、蛤蚧12g、海龙15g、海马15g、蚕蛹25g、石斛20g、壁虎15g、鹿角霜20g、白果20g、黄芪20g、地龙20g、芡实20g、薏苡仁25g、西洋参20g、天冬20g、肉苁蓉25g、黄精20g、五味子20g、牛膝20g、款冬花20g、三七参20g、鱼腥草20g、杜仲20g、太子参20g、天花粉20g、猫爪草25g、龟板30g、鳖甲30g和甘草15g。
实施例3
一种治疗弥漫性间质性肺纤维化肺炎中药组合物,包括以下重量的原料:人参须30g、麦冬25g、蝉蜕30g、白芨25g、茯神25g、丹皮25g、当归25g、蛤蚧15g、海龙20g、海马20g、蚕蛹30g、石斛25g、壁虎20g、鹿角霜25g、白果25g、黄芪25g、地龙25g、芡实25g、薏苡仁30g、西洋参25g、天冬25g、肉苁蓉30g、黄精25g、五味子25g、牛膝25g、款冬花25g、三七参25g、鱼腥草25g、杜仲25g、太子参25g、天花粉25g、猫爪草30g、龟板40g、鳖甲40g和甘草20g。
实施例4
实施例1~3所述的中药组合物的制备方法:
(1)预煎煮:将龟板和鳖甲混合后,加水,水浴煎煮,得混合药液A,备用;
(2)将权利要求1或2中其余原料混合置于水中浸泡后取出备用;
(3)煎煮:将混合药液A和步骤(2)浸泡后的原料混合得料B,置于水中浸泡,再加热煎煮,留药液,重复浸泡和煎煮,合并药液。
为进一步优化技术方案:步骤(1)煎煮的温度为100~102℃,煎煮时间为18~22min。
为进一步优化技术方案:步骤(1)龟板加鳖甲总质量与水的体积比为(4~8)g:(25~35)ml。
为进一步优化技术方案:步骤(2)水的温度为1~10℃,浸泡时间为85~95min。
为进一步优化技术方案:步骤(3)重复次数为一次;所述浸泡温度85~100℃,浸泡时间55~65min。
为进一步优化技术方案:步骤(3)煎煮的温度为100℃,煎煮时间为45~55min。
为进一步优化技术方案:料B和水的质量体积比为1g:(8~12)ml。
实验效果(部分典型病案):
病例1
病案分析:
病理:新型冠状病毒肺炎危重症康复后遗症。
张某,男,71岁,军医,湖北省武汉市人。
主诉:胸闷、气紧、气短心烦,近日加重。烦躁(新型冠状病毒康复后遗症)。
病史:患者于2020年1月17日发现咳嗽、胸闷于2020年1月18日在武汉大学中南医院CT肺部+纵隔(平扫-mpn)参见图1;
影像学诊断意见:双肺感染,病毒性肺炎,冠状少许粥样硬化,建议治疗后复查。
随即患者自我感觉胸闷、痰多、胃胀。
于2020年1月22日在中国人民解放军空降兵军医院进行CT检查双肺纵隔心脏,参见图2:
影像显示:
胸廓双侧对称,双肺纹理增多,部分边缘区胸膜稍粘连,双肺弥漫性“云雾状”稍高度模糊影可见,部分呈磨玻璃样改变,其内可见支气管通气征。
意见:
1、双肺弥漫性感染渗出性病变,病毒性感染可能。
2、左冠脉及主动脉弓局限性钙化斑形成。
患者发病一周后出现呼吸困难和低氧血症,可出现急性呼吸窘迫综合征,从传染科转呼吸科病房进行救治。在对症治疗的基础上,积极防治并发症,治疗基础疾病,以防继发感染,及时进行器官功能支持,采取应急措施:包括氧疗,充分液体复苏的基础上,改善微循环,使用血管活性药物,进行血流动力学监测。
经全力救治,病情趋于稳定,于2020年3月13日泰康同济(武汉)医院进行CT检查,检查部位:胸部及心脏CT平扫+三维成像;参见图3
影像所见:
双侧胸廓对称,双肺弥漫性,双肺下叶为甚。肺门及纵隔未见明显肿大淋巴结,纵隔未见移位,心脏形态大小未见异常,心包未见积液,左冠脉钙化灶。双侧胸腔未见积液,双侧胸膜未见增厚,扫及肝脏见多发状低密度形。
影像诊断:
双肺验证,请治疗后复查。
双肺间质性纤维化及支气管扩张。
左冠脉少许钙化灶。
根据患者呼吸困难程度以及胸部影像学的进展,给予抗病毒治疗和抗菌药物治疗,以及康复期免疫疗法(包括干细胞的临床试剂等治疗与观察)。
经一步治疗后,于2020年3月23日同济(武汉)医院CT检查;参见图4;
检查部位:胸部及心脏CT平扫+三维成像;
影像所见:
肺窗:原双肺炎症(新型冠状病毒肺炎),治疗后复查,现双肺野透过度增强,并见多发囊样透光影,两肺多发斑片条索影,边界不清,密度不均,以肺野外带分布为主,肺纹理增多、模糊、走行正常,肺门影不大,气管及支气管通畅。
纵隔窗:胸廓对称,胸膜增厚,双肺野内见散在条索影,各层面未见肿大淋巴结影,心脏增大,大血管未见异常,肝内见多个囊样低密度影,较大约2.6cm×1.5cm。
影像诊断:
1、原双肺炎症(新型冠状病毒性肺炎)治疗后复查,现两肺弥漫斑片影,与2020年3月8日大致相仿。
2、双肺肺气肿并肺大泡形成。
3、双侧胸膜增厚。
4、心影增大。
5、肝脏小囊肿。
在该院接收支持疗法和免疫治疗后。
于2020年3月29日转入六七二医院(中西医结合医院),在此期间进行康复结合治疗:
给予吸氧、雾化和静脉用药,止咳化痰等对症治疗和运动锻炼,康复隔离14天后回家。
出院诊断:
中医诊断:气阴两虚证,肺胀病。
西医诊断:1、肺气肿;2、慢性支气管炎并肺气肿;3、胆囊炎。
出院情况:患者诉:气喘、无力、胸闷、头晕明显好转,精神、食欲、睡眠可,体温正常、神志清楚、发育正常、营养正常等。
于2020年4月13日上午正式出院,遵照医嘱回家隔离14天,在家14天的隔离期间,从病患者微信反馈和本人的神色形态以及面部表情和舌色舌苔,发现新型冠状病毒肺炎康复后遗症仍然严峻。
在脱氧的情况下,行走和坐着就会出现喘息、心率加快、没精神、肌肉萎缩、全身乏力、饮食差;说话气息不够,掉氧,说不了一会就心慌气短。
于2020年4月23日开始远程就诊。
症候:形体消瘦(原体重180余斤,现体重140余斤),面色苍白,胸闷气短,呼吸困难,心慌头晕,食欲不振,烦躁缺氧,易怒,舌红舌中裂纹,脉涩而弦。
辩证:气阴两亏,脏腑实热,藴毒臃盛,津液亏损。
治法:润肺补肾,升清降浊,增补津液,健脾和胃,益气养血。
遵照实施例2组方制备并服用药物,谨守病机。于4月23日开始服药,服用至8月29日,每日服药3次,早晚平均150ml中午80~100ml。
患者反馈信息:服药后,烦躁逐渐减轻,次数减少,气力和体力逐渐增强,睡眠、饮食、大小便基本正常,有时大便开始干结,难以排出,容易心累,说话多一点儿就累,看手机电脑多一点也累。在适当调养的基础上继续服用中药,并于于2020年6月19日在武汉市第六医院做CT检查;参见图5;
影像表现:胸廓对称,气管居中,双肺纹理模糊。局部透明度增高,双肺小叶间隔增厚,呈网络状改变,气管及支气管畅通,左侧冠状动脉行走区见点状致密影,心影形态未见明显异常,心包及双侧胸膜腔内未见明显积液,纵膈内未见明显肿大淋巴结。
意见:
1、双肺间质性病变,建议结合相关检查。
2、肺气肿
3、左冠冠脉硬化
在调整治疗方案和用药方法后,继续服用本发明中药。
其中,6月10日开始不用带制氧气上厕所。于6月19日完全脱氧,室外活动逐步增多,距离也逐渐增大,步伐也逐步加快,呼吸及心率都没什么问题。饮食、睡眠、大小便都正常。
患者于2020年8月4日,中国人民解放军空降兵军医院进行CT检查,检查部位:CT,双肺纵膈心脏,参见图6;
影像显示:胸廓对称,双侧肺野纹理增多,增粗,模糊,部分边缘区胸膜稍增厚,双肺多发条索影,部分呈网格状改变,双肺多发含气空腔影,较大者大小约5.0×6.0cm,余双肺未见明显实质性病变影,双肺支气管畅通,双肺门不大,纵膈内未见确切淋巴肿,双侧胸膜腔未见积液征。左冠脉及主动脉弓局限性钙化影可见,心影大小、形态未见异常,心包腔未见积液影。
意见:
1、支气管炎
2、双肺多发肺大泡形成。
3、双肺多发陈旧性纤维条索灶,并轻度间质性改变。
4、左冠脉及主动脉弓局限性钙化斑形成。
至8月13日,患者身体机能日益提高,已可散步达一万多步,身体没有明显不适;心率66次/分,血压120/75(毫米汞柱),血氧:97%;晚间检测:心率74次/分,血压:125/80毫米汞柱,血氧:97%。
2020年10月19日,经湖北省中西医结合医院(湖北中医药大学附属新华医院)X射线检查报告显示,双肺,心隔未见明显异常,恢复良好(参见图7)。
同时,其他指征方面,5月11日舌苔表现为降红色,舌面中裂纹,舌两边芒刺。6月5日舌苔表现为红舌,舌面中裂纹,舌两边无芒刺。7月29日,舌苔淡红而明润,为阴阳气血旺盛,病情轻浅,疾病转愈之佳兆。淡红舌,舌面无裂。
本案是一位年过七旬的老人,刚发现轻微、干咳、乏力。1月18日到就近医院做CT检查,经检查,双肺感染病毒性肺炎可疑,第三天(1月22日)身体不适,又到某医院做CT检查,突然发现,双肺纹理增多,部分边缘区胸膜稍粘连,双肺弥漫性“云雾状”,稍高密度模糊影可见:部分呈磨玻璃样改变。
意见:双肺弥漫性感染渗出性病变,病毒性感染可能,经检查后,第三天(1月26日)患者处于昏迷状态,迅速住院,进入重症区间。此疫历属疫毒极强的病毒,短时间内具有极强的传播力。使呼吸系统、消化系统、免疫系统遭受重创。正如新感温病初起的受病部位,古人吴又可倡言邪自口鼻而入。叶天士《温热论》,又承吴氏之后,提出“温邪上受,首先犯肺,逆传心包”,两病之间有不谋而合之处。
患者经多家医院的积极救治,免疫系统得到收复,经各项检查均合乎标准,康复出院,但从影像学的角度来论证,本病仍存在明显的隐患:
一、弥漫性、间质性、纤维性、条索灶,仍然存在。另外,呼吸器吸氧昼夜携带,本身这三大板块到目前为止,都是医学难题,而又是新型冠状病毒肺炎病种所导致的。
本发明提供的中医中药具有在治疗新型冠状病毒肺炎后遗症这一病种有独特的优势,辩证论治的基础上;以固本清源,标本兼治,润肺补肾,散结化瘀、益气补血,在分化病毒的同时,将病理细胞逆转和修复为正常生理细胞。
不难看出,从患者的舌苔的转变,CT的报告以及本人的自述,佐证中医中药在治疗新型冠状病毒后遗症这一新型病种中起到事半功倍的效果,目前本病仍在继续干预调理中。
病例2
病案分析:
王某,女,80岁,山西长治市人。
于2017年5月29日前来就诊:
主诉:患者因胸闷、气短、心烦近日加重。
现病史:最近呼吸困难、胸闷、咳喘加重于2017年5月23日在长治医学院附属和平医院进行CT扫描报告(参见图8);
临床诊断:检查部位:胸部
影像学表现:
胸廓对称,气管纵隔居中,双肺多发磨玻璃改变,右肺上叶片状高密度影,右肺中叶片状高密度影,边缘锐利,右肺中叶见钙化结节灶,双肺纹理走形自然,诸支气管开口良好,纵隔内多发肿大钙化淋巴结。心影增大,心包腔少量积液。
影像学诊断:
1、右肺上叶间质性炎症,2、双肺间质性改变,3右肺中叶慢性炎症,4、右肺中叶钙化结节灶,5、纵膈内多发钙化淋巴结,6、心影大小包腔少量积液,请进一步检查。
近期的治疗病史如下:
2017年1月25日因哮喘入院于长治市人民医院。
于2017年1月26日长治市人民医院CT检查报告:
印象诊断:1、双肺多发局灶性炎症。2、纵膈多发淋巴结肿大。
3、双侧胸膜增厚。4、冠状动脉粥样硬化5、食道下端管壁不均匀增厚,请结合临床。
于2017年1月26日长治市人民医院CT检查报告:
检查部位:头颅
影像检查所见:双侧侧脑室周围及双侧半卵圆中心脑白质内可见多发斑片状密度减低区,其内可见多发点片状更低密度影,边界模糊,双侧大脑沟裂略增宽、加深,脑室系统略扩大,中线结构居中无移位。
影像诊断:双皮层下动脉硬化性脑病;请结合临床,必要时进一步检查。
该院完善诊断方案后,开始于2017年1月26日住院治疗,一直到2020年4月12日出院。
出院医嘱(参见图9):
建议:1、长期氧疗;2、继续使用长效支气管舒张剂(噻托溴铵吸入剂,18mg,1次/日,布地奈德福莫特罗吸入剂,1吸/次,2次/日)治疗;3、根据全身浮肿情况,间断口服利尿药物治疗,注意补充电解质;4、注意监测血糖变化,根据血糖调整胰岛素用量;5、继续给予冠心病二级预防治疗;6、不适随诊。
从出院医嘱已明确:双肺间质性肺炎这一病毒的存在需要长期氧疗的结论,结合近期CT诊断:右肺上叶间质性炎症,双肺间质性改变主要病理为双肺多发磨玻璃改变。
形体臃肿、气喘、气急、咳喘困难和紫绀均可明显,胸廓扩张和膈肌活动均减低,呼吸音粗糙靠氧气呼吸,全身浮肿,心慌头晕,食欲不振、烦躁易怒,舌红苔粘腻增厚,脉涩而弦细。
现病史和既往史相融合,进行周密的判断、分析、梳理,得出正确的方案,药病对症进行辩证施治:
辩证:气阴两虚、肺失需养、蕴毒臃盛、气滞血瘀
施治:润肺生津、健脾补肾、和胃养血、清热解毒、理气散结化瘀
遵照实施例2组方制备并服用药物,谨守病机,于2017年5月29日患者开始服药,服用至2017年9月,每日服药3次,早晚平均150ml中午80~100ml。
到2017年7月29日,患者开始下床行走,生活自理,全身浮肿现逐渐消失,烦躁心慌易怒症状有所改善,为摆脱长期吸氧的困惑,建议继续治疗。患者在家人的耐心照顾和关爱下,病情一天比一天好转,开始自理家务,有时有意拔掉呼吸器1~2小时,也没有出现任何不良反应,终于在2017年9月正式将氧气拔掉,除糖尿病史和冠心病史在继续用药外,其它症状都已恢复。
人体的呼吸运动主要与肺肾的功能相关。肺主气司呼吸,呼吸固然是肺的功能,其中呼气是靠肺的宣发作用,吸气是靠肺肃降作,但是吸气降纳,必须得到肾的摄纳作用的帮助,气根于肾亦归于肾,故曰肾纳气,其息深深。清代林佩琴指出:“肺为气之主,肾为气之根。肺主出气,肾主纳气,阴阳相交,呼吸乃和。”
本说明书中各个实施例采用递进的方式描述,每个实施例重点说明的都是与其他实施例的不同之处,各个实施例之间相同相似部分互相参见即可。
对所公开的实施例的上述说明,使本领域专业技术人员能够实现或使用本发明。对这些实施例的多种修改对本领域的专业技术人员来说将是显而易见的,本文中所定义的一般原理可以在不脱离本发明的精神或范围的情况下,在其它实施例中实现。因此,本发明将不会被限制于本文所示的这些实施例,而是要符合与本文所公开的原理和新颖特点相一致的最宽的范围。
Claims (10)
1.一种治疗弥漫性间质性肺纤维化肺炎中药组合物,其特征在于,包括以下重量份的原料:人参须20~30份、麦冬15~25份、蝉蜕20~30份、白芨15~25份、茯神15~25份、丹皮15~25份、当归15~25份、蛤蚧10~15份、海龙10~20份、海马10~20份、蚕蛹20~30份、石斛15~25份、壁虎10~20份、鹿角霜15~25份、白果15~25份、黄芪15~25份、地龙15~25份、芡实15~25份、薏苡仁20~30份、西洋参15~25份、天冬15~25份、肉苁蓉20~30份、黄精15~25份、五味子15~25份、牛膝15~25份、款冬花15~25份、三七参15~25份、鱼腥草15~25份、杜仲15~25份、太子参15~25份、天花粉15~25份、猫爪草15~30份、龟板20~40份、鳖甲20~40份和甘草10~20份。
2.根据权利要求1所述的一种治疗弥漫性间质性肺纤维化肺炎中药组合物,其特征在于,包括以下重量份的原料:人参须25份、麦冬20份、蝉蜕25份、白芨20份、茯神20份、丹皮20份、当归20份、蛤蚧12份、海龙15份、海马15份、蚕蛹25份、石斛20份、壁虎15份、鹿角霜20份、白果20份、黄芪20份、地龙20份、芡实20份、薏苡仁25份、西洋参20份、天冬20份、肉苁蓉25份、黄精20份、五味子20份、牛膝20份、款冬花20份、三七参20份、鱼腥草20份、杜仲20份、太子参20份、天花粉20份、猫爪草25份、龟板30份、鳖甲30份和甘草15份。
3.一种治疗弥漫性间质性肺纤维化肺炎中药组合物的制备方法,包括以下步骤:
(1)预煎煮:将龟板和鳖甲混合后,加水,水浴煎煮,得混合药液A,备用;
(2)将权利要求1或2中其余原料混合置于水中浸泡后取出备用;
(3)煎煮:将混合药液A和步骤(2)浸泡后的原料混合得料B,置于水中浸泡,再加热煎煮,留药液,重复浸泡和煎煮,合并药液。
4.如权利要求3所述的一种治疗弥漫性间质性肺纤维化肺炎中药组合物的制备方法,其特征在于,步骤(1)所述煎煮的温度为100~102℃,煎煮时间为18~22min。
5.如权利要求3所述的一种治疗弥漫性间质性肺纤维化肺炎中药组合物的制备方法,其特征在于,步骤(1)所述龟板加鳖甲总质量与水的体积比为(4~8)g:(25~35)ml。
6.如权利要求5所述的一种治疗弥漫性间质性肺纤维化肺炎中药组合物的制备方法,其特征在于,步骤(2)所述水的温度为1~10℃,浸泡时间为85~95min。
7.如权利要求6所述的一种治疗弥漫性间质性肺纤维化肺炎中药组合物的制备方法,其特征在于,步骤(3)所述重复次数为一次;所述浸泡温度85~100℃,浸泡时间55~65min。
8.如权利要求7所述的一种治疗弥漫性间质性肺纤维化肺炎中药组合物的制备方法,其特征在于,步骤(3)所述煎煮的温度为100℃,煎煮时间为45~55min。
9.如权利要求7所述的一种治疗弥漫性间质性肺纤维化肺炎中药组合物的制备方法,其特征在于,步骤(3)所述料B和水的质量体积比为1g:(8~12)ml。
10.权利要求1或2所述中药组合物或权利要求3~9任一方法制备的中药组合物在制备治疗新冠性肺炎药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011158979.7A CN112089800A (zh) | 2020-10-26 | 2020-10-26 | 治疗弥漫性间质性肺纤维化肺炎中药组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011158979.7A CN112089800A (zh) | 2020-10-26 | 2020-10-26 | 治疗弥漫性间质性肺纤维化肺炎中药组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112089800A true CN112089800A (zh) | 2020-12-18 |
Family
ID=73785765
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011158979.7A Pending CN112089800A (zh) | 2020-10-26 | 2020-10-26 | 治疗弥漫性间质性肺纤维化肺炎中药组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112089800A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112870314A (zh) * | 2021-01-20 | 2021-06-01 | 陈海林 | 一种治疗肾癌的中药组合物及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103816392A (zh) * | 2014-03-13 | 2014-05-28 | 成都中医药大学 | 一种治疗器官纤维化的药物组合物及其制备方法和用途 |
CN104225404A (zh) * | 2014-09-19 | 2014-12-24 | 香河县气管炎哮喘医院 | 一种治疗肺纤维化的药物组合物及其制剂 |
CN111228439A (zh) * | 2019-11-07 | 2020-06-05 | 陈海林 | 一种治疗肺癌和抗肺癌转移的中药组合物及其制备方法 |
-
2020
- 2020-10-26 CN CN202011158979.7A patent/CN112089800A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103816392A (zh) * | 2014-03-13 | 2014-05-28 | 成都中医药大学 | 一种治疗器官纤维化的药物组合物及其制备方法和用途 |
CN104225404A (zh) * | 2014-09-19 | 2014-12-24 | 香河县气管炎哮喘医院 | 一种治疗肺纤维化的药物组合物及其制剂 |
CN111228439A (zh) * | 2019-11-07 | 2020-06-05 | 陈海林 | 一种治疗肺癌和抗肺癌转移的中药组合物及其制备方法 |
Non-Patent Citations (4)
Title |
---|
何以蓓: "《徐志瑛学术经验集》", 31 May 2016, 中国中医药出版社 * |
张纾难等: "益肺化纤方治疗特发性肺纤维化临床观察", 《中国中医药信息杂志》 * |
王静: "《呼吸系统疾病检验诊疗》", 31 May 2017, 吉林科学技术出版社 * |
赵四林等: "新型冠状病毒肺炎重症、危重症恢复期患者的中医药治疗策略", 《湖南中医药大学学报》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112870314A (zh) * | 2021-01-20 | 2021-06-01 | 陈海林 | 一种治疗肾癌的中药组合物及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111388582B (zh) | 一种用于新型冠状病毒肺炎的中药组合物及其制剂的应用 | |
CN104225404B (zh) | 一种治疗肺纤维化的药物组合物及其制剂 | |
CN112089800A (zh) | 治疗弥漫性间质性肺纤维化肺炎中药组合物及其制备方法 | |
CN108324833A (zh) | 一种治疗结缔组织病相关性间质性肺病的中药制剂 | |
CN102416129A (zh) | 一种用于治疗缓解期慢性阻塞性肺疾病的中药 | |
CN102343029B (zh) | 一种治疗咳嗽的中药组合物制剂及其制备方法 | |
CN100553666C (zh) | 治疗慢性肺源性心脏病的药物及其制备方法 | |
CN111407878A (zh) | 一种治疗呼吸系统疾病的中药雾化组合物及其制备方法 | |
CN104306793B (zh) | 一种治疗大叶性肺炎的中药制剂 | |
CN1136880C (zh) | 一套治疗支气管哮喘的药物 | |
CN105232915A (zh) | 一种用于治疗特发性肺纤维化的中药组合物及其制备方法与用途 | |
CN107812176A (zh) | 一种治疗肺心病的中药组合物 | |
CN113082168A (zh) | 一种治疗肺癌的药物组合物及其应用 | |
CN113209218A (zh) | 治疗儿童室性早搏的中药组合物及其应用 | |
CN109223962A (zh) | 一种用于治疗尘肺病和肺纤维化的中药复方组合物及其制备方法 | |
Montanari et al. | Lung ultrasound monitoring of CPAP effectiveness on SARS-CoV-2 pneumonia: A case report | |
CN104189427B (zh) | 一种治疗风寒型咳喘疾病的中药组合物及其用途 | |
CN102743708B (zh) | 治疗肺气肿、肺心病、哮喘、慢性支气管炎的虫草蛤蚧粉 | |
CN109453325A (zh) | 一种治疗呼吸系统疾病的中药组合物及其制备方法和应用 | |
Canfield | LXIX. A Case of Rhinoscleroma in a Native Born American | |
CN1263491C (zh) | 抗柯萨奇b病毒性心肌炎胶囊及其制备方法 | |
CN115887472B (zh) | 甘露特钠在制备治疗肺纤维化疾病的药物中的应用 | |
CN102579785B (zh) | 肺康丸 | |
CN105687684A (zh) | 一种治疗慢性阻塞性肺疾病的中药制剂 | |
CN107625911A (zh) | 一种治疗痰热咳嗽的中药配方及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201218 |
|
RJ01 | Rejection of invention patent application after publication |